

• Florida Gun Gag Law Ruled Illegal

treating intractable cancers, said

Robert Getzenberg, MD, the Johns

Hopkins University School of Medicine researcher who coined the term "Lance Armstrong Effect" five years ago in a commentary in the *Journal of the American Medical Association*.

"We have not had much success with cancer," Getzenberg said. "There are few things that really work. Every drug we come up with, cancer develops a resistance to," Getzenberg said.

#### Old Idea Finds New Believers

For decades, doctors have known that heat can kill cancer cells. Dating back to the 1960s, small trials of combining heat and chemotherapy were conducted, but the treatment never caught on mainly because of its complexity and a lack of data showing a clear survival benefit, said H. Richard Alexander, MD, associate chairman of clinical research at the University of Maryland Medical Center.

But in the 1990s, Alexander and other researchers began finding benefit in difficult-to-treat cancers that had spread to the liver.

A one-two punch: Heat and chemo
In unconventional therapy for canoer that has spread to the liver, the liver is isolated from other organs. Heat weekens the canoer cells and makes them more susceptible to chemotherapy. Healthy tilissues in the rest of the body are not exposed to the chemo and its side effects.

Perfusion circuit
Liver is put on bypass. Healthy concentrated chemo and its side effects.

Perfusion circuit
Liver is put on bypass. Healthy concentrated chemo agent is have to be for one hour.

Vein bypass Blood returning to the heart from the load of the liver good by bypass of the liver good by bypass of the liver good by bypass of the load of the

"If (liver perfusion) were just a pill, the FDA would approve it immediately because it is as good as anything else we have tried," he said. "In some patients you see very dramatic results. In some cases, you can make tumors disappear from X-rays."



Mark Vetter and his wife, Nancy. Photo credit: Mike Sears, Milwaukee Journal Sentinel.

But tumors can come back. So far, the gold standard of research -- a large, randomized clinical trial -- has yet to be done. So data on the survival benefit remain lacking.

To date, most of the observational research suggests that average survival is extended about a year.

At the University of Pittsburgh Medical Center, about 25 liver perfusion cases are done a year, said cancer surgeon David Bartlett, MD.

Milwaukee Journal Sentinel.

Average survival is about two years, he said. About 5% of patients live five years. One man still is alive 12 years after undergoing the treatment. Bartlett said.

## Not Too Hot, Not Too Cold

At Froedtert, the doctors use a basic, highly invasive approach:

- Wheel the patient to the operating room
- Make a long incision in the abdomen
- Isolate the liver with clips, catheters, and cannulas, and perfuse it with the drug melphalan
- The drug is heated to about 102 degrees and mixed at concentration 20 times stronger than a standard chemotherapy dose

Others are in the early stages of testing more sophisticated methods for using heat and chemo, including the use of iron oxide and gold nanoparticles that have been chemically bonded with antibodies designed that seek out specific cancer cells. With the tiny metallic particles inside, the tumors, but not healthy tissue, then are heated using friction caused by radiofrequency or alternating magnetic field devices.

"We can heat them so much that we can burn them up," Getzenberg said.

The ideal approach, though, which now is being tested with prostate cancer in lab and animal models, involves heating the tumors to 107 degrees, which makes them much more vulnerable to chemotherapy agents, he said. Such nanoparticle and heat cancer therapies remain unproven and likely are a few years down the road

## The "If" Factor

From his perspective as a patient undergoing a newly discovered "old" therapeutic approach, the



#### **MedPage Today Tools**

## Guide to Biostatistics 🗖

Important epidemiologic concepts and common biostatistical terms to help clinicians translate medical research into everyday practice.

## **Chemotherapy News Feed Widget for Your Website**

Place a free, customizable RSS news feed widget on your website or blog. We've created over one-hundred widgets in each of our medical specialties. *more about widgets* 

# Chemotherapy specific RSS News feed for your reader, blog, or website

http://www.medpagetoday.com/medical-news-rss-feeds/Chemotherapy-Specific.xml



Google news

treatment is just one more "if" for Vetter.

If he had not gone in for a routine eye exam two years ago, doctors would not have found the tumor in his left eye and he might be dead -- he's one of about five in one million people a year who develop ocular melanoma, a disease that often metastasizes to the liver.

If he had preferred, he could have traveled hundreds of miles to one of a couple centers in the country that specialize in the unconventional treatment. Instead, he chose to be one of the first such patients to undergo that unconventional treatment at a center in his hometown.

Of course, there is the biggest if: if this treatment works, how long will he live?

At 66, Vetter, a Milwaukee area private labor attorney, is no Lance Armstrong.

He looks trim and fit, hardly like someone who had been battling an often fatal disease for more than two years.



Doctors at Froedtert Hospital, in Wauwatosa, Wis. performing isolated hepatic perfusion surgery on Mark Vetter. Photo credit: John Fauber, Milwaukee Journal

### The Process

The treatment Vetter underwent lasted about an hour, "the most tolerable duration," according to T. Clark Gamblin, MD, one of the Froedtert/Medical College of Wisconsin cancer surgeon who operated on Vetter.

The trick is to get the right mix of chemo, heat, and time so to be lethal to cancer cells without causing too much harm to healthy liver cells. While some normal liver cells may die, that's acceptable because the liver has the ability to regenerate tissue.

"You are putting the liver on bypass," said Kiran Turaga, MD, a Froedtert/Medical College cancer surgeon. "It's like the liver is out of the body."

Vetter's surgery was the second such case at the hospital and the latest in a long line of treatments he has tried.

As a veteran of the cancer war, he knows he will be undergoing continual monitoring in the months to come.

He also says he understands there is no way to know how much the treatment will help.

"I have not changed much of anything about the way I live my life," he said in a recent interview from his Milwaukee area home. "My goal is to be sitting in this room in 20 years."



Additional Chemotherapy Coverage >>



View Comments By: 

Healthcare Professionals

All

Contribute your own thoughts, experience, questions, and knowledge to this story for the benefit of all MedPage Today readers.



trond hildahl - Nov 21, 2011

I'm disappointed there is no mention of Celsion's Thermodox drug candidate - combining radiofrequency ablation with an encapsulated doxorubicin, allowing the heat to release the chemo directly into the ablation zone. -Trond Hildahl

		<b>↑</b> FEEDBAC	K			
	This report helped me st	ay abreast of new dat	a and medical dev	velopments.		
Strongly A				Strongly Disagree (1)		
	This report improves my ab	ility to have informed	conversations wi	th my patients.		
Strongly A	gree (5)			Strongly Disagree (1)		
	The information in this repo	ort will help me diagno	ose and treat patie	nts effectively.		
Strongly A	gree (5)			Strongly Disagree (1)		
	) (		0	0		
		Submit				
		Disclaimer				
		bo	TRELIS ceprevir	LEARN MORE		
MedPage Toda	y Professional				medpage	everyday -
everyday -	is for informational purpose  MEDPAGE TODAY, EXPE and TEACHING BRIEF an  Meeting Coverage   New	es only, and is not a sul ERT PATIENT, MEDPA e registered trademarks s By Specialty   Surve	bstitute for medical GE TODAY MOBIL s of MedPage Toda ys   Blogs   Video	advice, diagnosis or treatment   I.E., ADD YOUR KNOWLEDGE, y and Everyday Health, Inc. os   State CME Requirements	e Today's <u>terms of use</u> and <u>privacy policy</u> . T provided by a qualified health care provider. PUTTING BREAKING MEDICAL NEWS IN   CME/CE Tracker   RSS Feeds   About Technical Requirements   Terms of use	Sunguard TO PRACTICE

Code: N